

# FendX Technologies' Dr Carolyn Myers Provides REPELWRAP Film Manufacturing Dunmore Partnership Update

written by InvestorNews | March 6, 2024

In a recent interview with Tracy Weslosky, Dr. Carolyn Myers, President, CEO, and Director of [FendX Technologies Inc.](#) (CSE: FNDX | OTCQB: FDXTF), shared insights into the progress and strategic initiatives surrounding their groundbreaking REPELWRAP™ film, a film that significantly reduces adhesion of bacteria and viruses on surfaces. Collaborating with Dunmore International Corp., their manufacturing partner, FendX has achieved pivotal advancements in automating and refining the production process of REPELWRAP™ film, targeting efficiency enhancements such as reduced changeovers and optimized heating and drying phases. These improvements are key to streamlining production and ensuring the product is cost-effective without sacrificing performance.

Dr. Myers emphasized the critical next steps involving rigorous real-world testing to confirm the film's durability and efficacy against bacteria and viruses in varied environments, including healthcare and other high traffic venues. Such testing, previously conducted in McMaster University's lab, demonstrated the film's promising potential. FendX aims to transition to commercial production by the year's end, with aspirations to begin revenue generation in the first half of 2025.

The partnership with McMaster University, which facilitated the exclusive licensing of the nanotechnology IP for REPELWRAP™ film, was highlighted as instrumental in meeting developmental

milestones. The strategic relationship with Dunmore was also underscored as vital for advancing the product towards commercialization. Dr. Myers exemplifies a commitment to delivering innovative solutions designed to mitigate pathogen transmission on surfaces, marking a significant leap towards enhancing public health safety.

To access the complete interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#)

## About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., [click here](#)

***Disclaimer:*** FendX Technologies Inc. is an advertorial member of InvestorNews Inc.

*This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the "Company"), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.*

*This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.*

*Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or*

*results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on [www.sedarplus.ca](http://www.sedarplus.ca) and to carry out independent investigations in order to determine their interest in investing in the Company.*

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investornews.com](mailto:info@investornews.com).

---

## **Greg Fenton Discusses Zentek's 2024 Progress and Exclusive Aptamer Technology Rights**

written by InvestorNews | March 6, 2024

In a detailed interview with Tracy Weslosky, Greg Fenton, CEO and Director of [Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN), shared insights into the company's strategic progress and emerging opportunities, particularly emphasizing its work with aptamer technology. With an exclusive global license for innovative Aptamer-based platform technology developed by McMaster University, Zentek is pioneering advances in both diagnostic and therapeutic applications, underscoring its dedication to

healthcare innovation. The company has made notable breakthroughs in COVID-19 therapeutics with its [C19HBA aptamer](#), showing significant promise in preclinical trials by outperforming leading monoclonal antibodies. This success has paved the way for Phase 1 clinical trials for COVID-19 and exploration into other areas such as oncology, immunology, and neurology.

Fenton highlighted the positive reception from major pharmaceutical companies, reflecting a broad industry interest in Zentek's aptamer technology. Additionally, Zentek's ZenGUARD™ technology platform, known for its 99-percent anti-microbial activity, has been instrumental in enhancing the bacterial and viral filtration efficiency of surgical masks and HVAC systems. A [recent study](#) on ZenGUARD™ Enhanced Air Filters revealed its potential to offer significant energy, emission, and cost savings for commercial buildings, showcasing a scalable solution for improving indoor air quality and addressing climate change.

Throughout the conversation, Fenton articulated Zentek's ambitious plans for partnerships and expansion, leveraging the favorable market conditions to boost the company's visibility and impact. His vision for Zentek includes strategic partnerships, leveraging its proprietary technology, and a commitment to revolutionizing the approach to managing infectious diseases and enhancing environmental sustainability.

To access the complete interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

## About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property

technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek, through its wholly-owned subsidiary Triera Biosciences Ltd., has a global exclusive license to the Aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

The Company is not making any express or implied claims that its aptamer technology has the ability to eliminate, cure or contain COVID-19 (or the SARS-CoV-2 coronavirus) at this time.

To learn more about Zentek Ltd., [click here](#)

**Disclaimer:** Zentek Ltd. is an advertorial member of InvestorNews Inc.

*This interview, which was produced by InvestorNews Inc. ("InvestorNews"), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.*

*This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.*

*Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the*

*Company's profile on [SedarPlus.ca](https://www.sedarplus.ca) and to carry out independent investigations in order to determine their interest in investing in the Company.*

---

# **Dr. Carolyn Myers on FendX Technologies' Breakthrough Film Formulation that Kills and Repels Bacteria**

written by InvestorNews | March 6, 2024

In an insightful interview with Tracy Weslosky from Investor.Coffee, Dr. Carolyn Myers, President, CEO, and Director of [FendX Technologies Inc.](#) (CSE: FNDX | OTCQB: FDXTF), shared significant advancements in nanotechnology relating to antimicrobial films. FendX, having licensed original technology from McMaster University in 2021, [has developed](#) a unique film formulation that both repels and kills bacteria. This breakthrough, achieved through collaboration with McMaster, involves using photoactive nanoparticles, titanium dioxide (TiO<sub>2</sub>), which not only serves as a linker in the chemical composition of the film surface but also exhibits killing properties when exposed to light.

Dr. Myers highlighted the exceptional efficiency of this formulation, with the film showing nearly 100% repelling properties (99.8% precisely) and a 99.6% effectiveness in killing residual bacteria. This dual-action capability sets this formulation apart in the market, offering a potentially future



superior alternative to existing films that either repel or kill pathogens. FendX's current focus is on producing REPELWRAP™ film, which specializes in repelling bacteria and viruses.

The film formulation referenced in the November 29, 2023, [news release](#), is created by activating the substrate (i.e., plastic like Saran wrap), then coating it with TiO<sub>2</sub> and fluorosilane followed by thermal shrinking creating a surface that significantly prevents bacterial adhesion. Dr. Myers contrasted FendX's technology with other existing surface protection films that effectively kill microbes when they come in contact with the film surface, but this takes time leaving a potential window of opportunity for transmission before the bacteria are killed.

In terms of applications, Dr. Myers emphasized the potential versatility of FendX's technology, with the company developing both film and spray products. The primary application areas include healthcare and other high-traffic environments. The spray technology, still in early development, promises even broader applications due to its ease of application.

To access the complete interview, [click here](#)

Don't miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by [clicking here](#)

## About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their

transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has an exclusive worldwide license to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

To learn more about FendX Technologies Inc., [click here](#)

**Disclaimer:** *FendX Technologies Inc. is an advertorial member of InvestorNews Inc.*

*This interview, which was produced by InvestorNews Inc., does not contain, nor does it purport to contain, a summary of all material information concerning FendX Technologies Inc. (the "Company"), including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.*

*This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-*

looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on [www.sedarplus.ca](http://www.sedarplus.ca) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investornews.com](mailto:info@investornews.com).

---

# Greg Fenton on how Zentek's Advancement in Aptamer Technology is Revolutionizing Biotech

written by InvestorNews | March 6, 2024

In an interview with host Tracy Weslosky from InvestorNews, [Zentek Ltd.](#)'s (NASDAQ: ZTEK | TSXV: ZEN) CEO Greg Fenton began their discussion on the substantial improvement in the aptamer platform's binding affinity and yield as announced in their [November 15th, 2023, release](#). Greg explains how the new platform may reduce the rapid clearance from the body, the researchers have increased the aptamer platform production to a 95% yield, which substantially reduces costs and positions them as potential replacements for monoclonal antibodies, offering efficiency and cost benefits.

Fenton highlights the rapid production capability of aptamers, taking only 6-8 weeks compared to longer durations for vaccines. Aptamers, composed of DNA sequences, are deemed safe and can be synthesized quickly for specific targets. This speed and cost-effectiveness give aptamers a competitive edge in the market, especially against antibody therapies.

He also discusses Zentek's collaboration with McMaster University in medical research, noting that the aptamer platform is still in early stages but shows great potential. He emphasizes the importance of safety, dosing ranges, and further research to establish the platform's market value.

Additionally, Zentek's recent developments include ZenGUARD™ enhanced air filters, which offer significant cost savings in

healthcare and energy efficiency. The filters reduce absenteeism and energy costs by requiring fewer air exchanges, representing economic benefits for building owners, businesses, and public healthcare systems.

Fenton also remarks on Zentek's efficient use of funds, highlighting that their current stage of development would typically cost hundreds of millions of dollars, but they achieved it with a fraction of that amount. This efficiency is attributed to their partnership with McMaster University.

Finally, the addition of John Snisarenko, a former pharma industry executive, to Zentek's board is seen as a strategic move to enhance the company's outreach and partnership engagement in the pharmaceutical industry. His extensive pharmaceutical experience and connections are expected to be valuable for Zentek's future development and commercialization strategy.

The news release from November 15, 2023, corroborates these developments, noting the substantial improvement in the aptamer platform's binding affinity and yield. The release also highlights the potential for Zentek's aptamers in precision therapy, competing with monoclonal antibodies, and the significant cost and timeline advantages inherent to their platform technology. Zentek's CEO comments on the potential of the aptamer platform across various therapeutic areas and the company's shift towards commercialization and partnership strategies. To access the complete interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

# About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek has a global exclusive license to the Aptamer-based platform technology developed by McMaster University which is being jointly developed Zentek and McMaster for both the diagnostic and therapeutic markets.

To learn more about Zentek Ltd., [click here](#)

**Disclaimer:** *Zentek Ltd. is an advertorial member of InvestorNews Inc.*

*This interview, which was produced by InvestorNews Inc. ("InvestorNews"), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.*

*This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form*

part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on [SedarPlus.ca](https://www.sedarplus.ca) and to carry out independent investigations in order to determine their interest in investing

*in the Company.*

---

# **FendX Technologies is a germaphobes new best friend**

written by InvestorNews | March 6, 2024

How often do you find yourself with subtle post pandemic habits, like pushing doors open with your elbow or forearm, or perhaps you pull your jacket sleeve down over your hand to pull open a door handle? Basically, you are trying to avoid public touch points that have the potential to carry some sort of germs or bugs or other nasties that you'd rather not have on your hands. Things can be even worse in places like hospitals where viruses are an ordinary part of daily life and you can potentially cross paths with some really nasty, antibiotic resistant pathogens. But before I scare you into being afraid to leave the house, have faith that help is on the way.

---

## **FendX Technologies' award winning nanotechnology and REPELWRAP™ film is advancing**



# at warp speed

written by InvestorNews | March 6, 2024

One day in the future there could be special nanomaterials used in hospitals, operating theaters, and medical clinics that act to repel pathogens (viruses, bacteria, etc). The applications for pathogen repelling materials are almost endless. Think of surgical equipment, catheters, and perhaps even our personal gadgets.

---

## **Revolutionary Aptamer-Based Pathogen Technology from Zentek Unveils Rapid and Inexpensive Pathogen Detection Capabilities**

written by InvestorNews | March 6, 2024

A Canadian company and their laboratory partner have developed a low cost simple and much faster way to better detect pathogens causing infections in our bodies. In recent weeks the team found a way to dramatically improve the effectiveness of this technology, which is really a medical breakthrough you won't likely see on the news, at least not just yet. Their technology uses 'aptamer' based diagnostics from a simple saliva test.

# What is an aptamer?

Aptamers are short sequences of artificial DNA, RNA, XNA, or peptide that bind a specific target molecule or family of target molecules. In the case of today's company, they are using single-stranded DNA molecules capable of binding specifically with target proteins on the surface of pathogens such as SARS-CoV-2 to detect if a person has COVID-19 or potentially other pathogens.

## Zentek Ltd.

[Zentek Ltd.](#) (NASDAQ: ZTEK | TSXV: ZEN) ("Zentek") is a certified graphene technology company focused on the research, development and commercialization of graphene-based novel products, typically using nanotechnology.

Zentek's aptamer-enabled [Pathogen Detection Technology](#) is a low-cost, rapid, saliva testing, scalable technology initially to be used for COVID-19 testing, but can be adapted to detect other pathogens. Zentek has [exclusive worldwide rights to commercialize](#) their COVID-19 antigen testing aptamer-enabled technology. The technology is being developed by Zentek and their technology partners at McMaster University Li Lab, led by Dr. Yingfu Li.

Zentek's collaboration with McMaster University extends beyond its exclusive license and now encompasses all aptamer and DNAzyme uses, including diagnostics, therapeutics, and neutralization agents, not limited solely to SARS-CoV-2 applications.

# Aptamer technology breakthrough, up to 250 times increase

Zentek recently announced a breakthrough in the team's aptamer-enabled technology, [stating](#):

*"Dr. Yingfu Li and his team at the Li Lab have developed a novel aptamer technology that increases the binding affinity of aptamers by up to 250 times. The increased binding affinity enhances the limits of detection for aptamer-based diagnostics. In addition, the enhanced binding affinity may lead to the successful adaptation of these same aptamers for new therapeutic and prophylactic treatments. Binding affinity is a key metric in both diagnostic and therapeutic applications."*

Understandably most people will not understand the implications of what is going on here, so I will spell it out. Effective Aptamer-based pathogen technology opens up a whole new potential to 'rapidly and cheaply' detect pathogens. In time this can be expanded to potentially detect other markers of disease in the body. Furthermore, it has the potential to more effectively treat diseases. But that's the next chapter, best discussed another time and assuming Zentek continues down that pathway.

Dr. Yingfu Li recently [stated](#):

*"The novel aptamer technology platform developed in my lab at McMaster University is demonstrating a robust increase in binding affinity to every aptamer we have tried so far. Combining this technology with aptamers that have high specificity **has created a very exciting potential for new therapeutics and diagnostics.** The enhanced binding affinity from these new aptamers has led to **consistent and successful in vitro testing** in my lab and the lab of Dr. Leyla Soleymani for*

*diagnostic applications, and more recently, with in vivo testing in the lab of Dr. Matthew Miller for therapeutic applications. These early results are very exciting, and we look forward to future work that applies the technology to other potential therapeutic and diagnostic targets.”*

*Note: Bold emphasis by the author.*

## **The advantages of Zentek’s aptamer technology for detecting Covid-19 or potentially other pathogens**

**The advantages of Zentek's aptamer technology are:**



- **Simplicity & Comfort** – uses saliva rather than a nasal swab reducing aversion to testing and risk of error in the sampling process
- **Accuracy** – electrochemical sensing technology rather than lateral flow allows for sensitivity equivalent to a 36 count RT PCR
- **Mobility** – simple hardware lends itself to easy transport and high throughput, point-of-care testing
- **Speed** – results in under 10 minutes
- **Low Cost** – aptamers can be developed more quickly and cost effectively compared to antibodies allowing us to be highly competitive compared to currently available rapid detection tests now and into the future
- **Scalability** – new aptamers can be developed to detect numerous other pathogens giving our technology the ability to enhance safety and empower businesses, governments and our healthcare providers well beyond COVID

Source: [Zentek website](#)

The potential for aptamer-based disease detection is truly remarkable. There is also potential one day that aptamers can be used to much more precisely target disease treatment or prevention in the body.

Greg Fenton, CEO of Zentek [commented](#):

*“Initially, we were working to develop aptamers for diagnostic purposes.....Dr Li’s initial breakthrough was important for diagnostic purposes, and now early testing points to the*

*potential to create new therapeutics and prophylactics. I can't emphasize enough how unexpected these results were to our team and how significant this development is if it is confirmed through future testing."*

For more details, investors can watch the recent Zentek CEO interview [here](#).

Zentek is now at the stage of commercializing their aptamer-enabled technology [stating](#) that they are "commercial prototyping readiness, and working with [Halteres Associates](#), a world-leading bioscience consultancy, to assist us in our commercialization process."

## Zentek's product pipeline

### Graphene Pipeline: What We're Working On

**zentek**



**We know graphene: a key building block for a healthier and more sustainable future**

Source: [Zentek company presentation](#)

## Closing remarks

There is no more exciting company than Zentek. Apart from their aptamer technology Zentek has many other applications for their graphene nanotechnology including: [ZENGuard™](#) (a graphene coating applied to PPE to prevent Covid and other infections; also used for air filtration (HVAC) systems), [icephobics](#) (to prevent ice build up on planes etc), ZENArmor (corrosion resistance), [fuel additives](#) (helping reduce carbon emissions), [Graphene-wrapped silicon anodes](#), [conductive inks](#), [intumescent coatings](#), and [anti-inflammatory therapies](#).

Furthermore, Zentek makes their own graphene oxide at their Guelph facility and owns the Albany Graphite Deposit ([planned to be spun out](#)).

Zentek Ltd. trades on a market cap of [C\\$216 million](#). With commercialization of ZENGuard™ underway and Zentek's aptamer technology potentially to follow soon, Zentek is at a great stage to rapidly grow from here. Stay tuned in 2023 to see how Zentek performs and if they can successfully start to monetize their technology.

---

**Greg Fenton on how ZEN Graphene's disease detection technology will "revolutionize**

# the way testing is done”

written by InvestorNews | March 6, 2024

In a recent InvestorIntel interview, Tracy Weslosky speaks with Greg Fenton, CEO and Director of [ZEN Graphene Solutions Ltd.](#) (TSXV: ZEN) about ZEN’s [exclusive worldwide rights](#) to commercialize rapid, saliva-based COVID-19 antigen testing technology announced yesterday

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg went on to say that this saliva-based test is exceptionally accurate, similar to current PCR tests, and will “revolutionize the way testing is done”. Affordable, easy to use, scalable and provides results in under 10 minutes, Greg comments that this technology has the ability “to allow economies to reopen.” Tracy then asks the critical question with “will you be able to test for anything?”

To find out – watch the full interview, [click here](#)

## About ZEN Graphene Solutions Ltd.

ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing **ZEN Guard**™, a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive



advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN's Albany Pure™ Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

**Disclaimer:** ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or



results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on [www.Sedar.com](http://www.Sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [info@investorintel.com](mailto:info@investorintel.com).